Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cancer drugs
CRO
Australian biotech partners with Pi Health for cancer trial
The phase 1/2 ADVICE trial of kesonotide, a vimentin inhibitor, is intended to be the first of many collaborations between Pi Health and Filamon.
Darren Incorvaia
Sep 4, 2025 8:30am
Servier hands Ideaya $210M upfront for ex-US rights to PKC asset
Sep 2, 2025 3:02pm
Cell therapy biotech Appia shuts down as funding runs dry
Aug 25, 2025 5:55pm
FDA draft recommends all cancer trials collect OS data
Aug 20, 2025 10:59am
Genentech scraps $2B cell therapy pact with Adaptive
Aug 18, 2025 2:40pm
Prelude calls it curtains on lead SMARCA2 cancer asset
Aug 14, 2025 10:44am
